CN1895667B - Reovirus inactivated vaccine and its preparation - Google Patents
Reovirus inactivated vaccine and its preparation Download PDFInfo
- Publication number
- CN1895667B CN1895667B CN200610012792XA CN200610012792A CN1895667B CN 1895667 B CN1895667 B CN 1895667B CN 200610012792X A CN200610012792X A CN 200610012792XA CN 200610012792 A CN200610012792 A CN 200610012792A CN 1895667 B CN1895667 B CN 1895667B
- Authority
- CN
- China
- Prior art keywords
- virus
- reovirus
- vaccine
- gallus domesticus
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000702263 Reovirus sp. Species 0.000 title claims description 19
- 229940031551 inactivated vaccine Drugs 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 10
- 241000700605 Viruses Species 0.000 claims abstract description 48
- 241000287828 Gallus gallus Species 0.000 claims abstract description 31
- 229960005486 vaccine Drugs 0.000 claims abstract description 17
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 13
- 210000002966 serum Anatomy 0.000 claims abstract description 10
- 241001516406 Avian orthoreovirus Species 0.000 claims abstract description 8
- 230000003612 virological effect Effects 0.000 claims description 17
- 210000001161 mammalian embryo Anatomy 0.000 claims description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 14
- 210000003837 chick embryo Anatomy 0.000 claims description 12
- 210000002950 fibroblast Anatomy 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 230000009849 deactivation Effects 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000009395 breeding Methods 0.000 claims description 6
- 230000001488 breeding effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 230000011218 segmentation Effects 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 241001440741 CHER virus Species 0.000 claims description 3
- 206010011732 Cyst Diseases 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 3
- 230000023555 blood coagulation Effects 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 231100000915 pathological change Toxicity 0.000 claims description 3
- 230000036285 pathological change Effects 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000011218 seed culture Methods 0.000 claims description 3
- 210000001835 viscera Anatomy 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims 6
- 239000008346 aqueous phase Substances 0.000 claims 2
- 239000000463 material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 241000272496 Galliformes Species 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000036039 immunity Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 5
- 206010003274 Arthritis viral Diseases 0.000 description 4
- 208000004575 Infectious Arthritis Diseases 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 208000004760 Tenosynovitis Diseases 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000008104 Reoviridae Infections Diseases 0.000 description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003555 cloaca Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000009361 aviculture Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- ILRLTAZWFOQHRT-UHFFFAOYSA-N potassium;sulfuric acid Chemical compound [K].OS(O)(=O)=O ILRLTAZWFOQHRT-UHFFFAOYSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A deactivated Avianreovirus vaccine for fowls is prepared from the Avianreovirus (ARV) RS13 (CGMCC No.1713) through separating said virus from the organ of infected chicken, serum test, reproduction of virus, deactivating, and emulsifying.
Description
Technical field
The present invention relates to a kind of viral vaccine and preparation method, specifically, is the preparation method of a kind of reovirus and vaccine, belongs to the medical product technical field.
Background technology
Avianreovirus (Avianreovirus, be called for short ARV) be chicken viral arthritis and tenosynovitis main pathogen it
One, belong to Reoviridae, the member that reovirus belongs to.Since Fahey and Grawly (1954) were separated to (ARV) from the chicken respiratory of suffering from chronic respiratory tract disease first, many ARV separated strains were in the news in succession.Along with carrying out in a deep going way of research, the relation of ARV and other disease is also paid close attention to by people.Have been found that except that viral arthritis and tenosynovitis, ARV plays a part to a certain degree in the generation of diseases such as respiratory tract disease, intestinal disease, the sick damage of conscience, blue wing disease, the short and small syndrome of broiler, temporary digestive system disorder, all can be separated to ARV in the chicken body of suffering from these diseases.ARV worldwide exists, and is widely current in chicken, turkey, and other birds infects ARVS also report.Loss economically often is that feed conversion rate is low owing to arthritis, tenosynovitis cause discarded rate height and growth inhibited.Flourish along with aviculture, the influence of ARV is increasing, and its disease incidence that causes rises, and complexity increases.At present, the main means of control fowl group ARV morbidity are to use attenuated live vaccine or inactivated whole virus vaccines to control typical chicken reovirus infection by immunity inoculation.But because this virus is RNA viruses, a plurality of segmentations are arranged, ubiquity in commodity fowl group, between different strains in antigenic structure, pathogenic, cell culture characteristic, have certain difference on to trypsin sensitivity and host specificity.When genetic evolution, morph easily, the difference between two kinds of viruses of zones of different is bigger.Use external vaccine for the native country should virus prevention and treatment be not very desirable, and price is very high.Therefore, at this viral serotype of the specific existence of China, the vaccine of the former unexistent special advantage of Development and Production can play a positive role to control native country fowl group ARV morbidity undoubtedly, and can produce favorable economic benefit.
Summary of the invention
Technical problem to be solved by this invention is: provide that a kind of immunity produces rapidly, longer duration, immunity are strong, at the reovirus inactivated vaccine and the preparation method of native country fowl group viral arthritis disease.
The alleged problem of the present invention is solved by following technical scheme:
A kind of reovirus, described virus be Avianreovirus (Avianreovirus, ARV), strain is the RS13 strain, preserving number was CGMCC No.1713, was deposited in Chinese microbial preservation administration committee common micro-organisms center on May 16th, 2006.
Above-mentioned reovirus inactivated vaccine, described reovirus does not have cyst membrane, be 20 body symmetries, genome is made of 10 double-stranded RNA segmentations, can tolerate 60 ℃ of 8～10h, insensitive to ether, to the chloroform slight sensitive, to the alkali sensitivity, 3% sodium hydroxide effect 1h, can kill virus, no blood clotting characteristic.
A kind of reovirus inactivated vaccine preparation method, it comprises the steps:
A. isolated viral: the position isolated virals such as feces, cloaca swab, stndon sheath and trachea the sick chicken of native country viral arthritis disease, with the washing of PBS buffer, filter, multigelation, discharge virus, virus is bred on Embryo Gallus domesticus or chick embryo fibroblast go down to posterity, make virus titer reach 10
10.5ELD
50/ 0.2ml uses viral seed as producing;
B. serum detects: with in the S1133 positive serum and after, inoculate in 10 age in days SPF Embryo Gallus domesticus or the chick embryo fibroblast, corresponding Embryo Gallus domesticus body and internal organs pathological changes or corresponding cytopathy do not appear, confirm that this viral serotype is identical with S1133;
C. virus breeding: seed culture of viruses bred on Embryo Gallus domesticus or chick embryo fibroblast go down to posterity, virus titer is detected reach 10
10.5ELD
50/ 0.2ml;
D. vaccine inactivation: formalin-inactivated 16 hours, formalin concentration are 34%, and addition is 2 ‰ of a deactivation liquor capacity; (actual pure concentration of formaldehyde is 0.64 ‰)
E. oil phase preparation: in white oil, add aluminium stearate, boil by 5 ‰ (volume/volume) adding Si Ben-80 and form by 2 ‰ (weight/volume);
F. emulsifying: add emulsifier tween-80, tween 80 accounts for 1% of water volume, and water and oil phase volume ratio are 3: 5, with 12000 rev/mins of emulsifyings 10 minutes, makes inactivated vaccine with mulser.
Above-mentioned reovirus inactivated vaccine preparation method, described breeding was gone down to posterity for 35～45 generations.
The present invention isolates reovirus from native country fowl group infects the sick chicken of ARV; the reovirus that separation is obtained goes down to posterity on Embryo Gallus domesticus some generations; make inactivated vaccine; be applied to immune chicken; produce immunne response in 1 week, can produce strong immunity in 2 weeks, duration of immunity is 2～2.5 months; the counteracting toxic substances protective rate is 94.8%～98.8% between duration of immunity, apparently higher than external import vaccine protective rate.This vaccine to China should virus prevention and treatment be even more ideal selection, be adapted to domestic each poultry-farm, safe and reliable, has very big actual application value, can remedy at present domestic aspect the reovirus infection defective of vaccine vacancy, for the control of this disease provide a kind of can practicable inactivated vaccine.
The specific embodiment
Vaccine of the present invention is at native country reovirus RS13 strain, this virus does not have cyst membrane, is 20 body symmetries, and genome is made of 10 double-stranded RNA segmentations, heat there is resistance, can tolerate 60 ℃ of 8～10h, insensitive to ether, to the chloroform slight sensitive, to the alkali sensitivity, 3% sodium hydroxide effect 1h can kill virus, and this virus does not have the blood clotting characteristic.
This virus is grown in Embryo Gallus domesticus easily, can select yolk sac inoculation for use when separating for the first time, general 3～5 days chicken embryo deaths after inoculation, and Embryo Gallus domesticus is purple because of extensive subcutaneous hemorrhage.During the allantocherion inoculation, death in common 7～8 days, allantocherion has protuberance slightly, dispersive white focus, Embryo Gallus domesticus mild dysplasia.
This virus also can be bred on chick embryo fibroblast, but needs to adapt to, and promptly adherent cell 1h often forms syncytium, comes across 24～48 hours the earliest, occurs the cavity after the cell monolayer degeneration subsequently, and giant cell is suspended in the culture medium.
Below provide the embodiment of preparation inactivated vaccine:
A. isolated viral: from feces, cloaca swab (if other sick chicken of the sick chicken of ill toxicity arthritis, then extract at other diseased region) in isolated viral, (add sodium chloride 8g in the 1000ml water with the PBS buffer, potassium chloride 0.2g, potassium dihydrogen sulfate 0.12g, sodium hydrogen phosphate 0.91g) washing, filter, multigelation 5 times discharges virus, separates to obtain virus.This virus was bred for 45 generations on chick embryo fibroblast, detect virus titer, reach 10
10.5ELD
50/ 0.2ml gets the 45th and withholds and obtain virus, uses viral seed as producing.
In the test that the present invention carries out, when virus through 45 generations of continuous passage, virulence weakens during obviously than separation just, but still virulence is stronger.The virus that goes down to posterity from the detection of tiring of the virus in continuous 10 generations in the 35th generation to 45 generations, all can be reached very high numerical value, promptly 10
10.5ELD
50About/0.2ml, illustrate that this virus has adapted in chick embryo fibroblast to breed, and highly stable.From virulence attenuation of, stable, the safety, effective of virus multiplication, prove that this virus is adapted at producing large-scale application.Simultaneously, also conclusion unanimity therewith of the result of study of clinical trial.
B. serum detects: with in the S1133 positive serum and after, in the inoculated into chick embryo fibroblast, corresponding cytopathy does not appear, confirm that its serotype is identical with S1133.
C. virus breeding: virus with 1: 10000 ratio inoculated into chick embryo fibroblast, was adsorbed 0.2ml/ piece of injection 1 hour, 37.5 ℃～38.5 ℃ of conditions cultivate, and cultivate a few days, 90 hours harvestings and nutritional solution, measure viral level, virus went down to posterity for 45 generations, virus titer is detected reach 10
10.5ELD
50/ 0.2ml.
D. vaccine inactivation: formalin-inactivated 16 hours, the formaldehyde that accounts for deactivation liquor capacity 2 ‰ (effective ingredient is 0.68 ‰) amount with analytical pure formalin (concentration 34%) joins in the viral liquid, and 37 ℃ of effects 16 hours shook up once in per 2 hours.
E. emulsifying: add emulsifier tween-80, tween 80 accounts for 1% of water volume, and water and oil phase volume ratio are 3: 5, and wherein water promptly is the viral liquid of deactivation, the white oil that oil phase is used during for emulsifying.With 12000 rev/mins of emulsifyings of mulser 10 minutes, make reovirus inactivated vaccine, every 0.2ml contains virus quantity 10
3.5ELD50.
This vaccine is the Water-In-Oil type through property determination, has good stability modest viscosity.Vaccine was placed 3 months at 20 ℃, placed 9 months, and layering do not occur for 4 ℃.
Safety check: 10 times of amounts of getting using dosage are 10
4.5ELD
50/ 0.2ml foot-pad immunization 1 age in days SPF chicken observed for 2 weeks, and situations such as footpad inoculation position NIP reaction occur.
Imitate inspection: getting using dosage is 10
3.5The subcutaneous immune 1 age in days chicken of ELD50/0.2ml nape portion after 2 weeks, is used strong virus attack, and protective rate reaches 100%.The immunity chicken produces immunne response in 1 week, in 2 weeks, can produce strong immunity, and duration of immunity is 2 months, and the counteracting toxic substances protective rate is 95.2%～98.8% between duration of immunity.
Claims (2)
1. a reovirus inactivated vaccine is characterized in that: reovirus was bred for 35～45 generations, gather in the crops virus, detect its virus titer and reach 10
10.5ELD
50Use viral seed as producing behind/the 0.2ml, went down to posterity for 35～45 generations through serum detection, virus breeding, virus titer detects and reaches 10
10.5ELD
50/ 0.2ml, again through vaccine inactivation, emulsifying, make reovirus inactivated vaccine;
Described serum detect be with in the S1133 positive serum and after, inoculate in 10 age in days SPF Embryo Gallus domesticus or the chick embryo fibroblast, corresponding Embryo Gallus domesticus body and internal organs pathological changes or corresponding cytopathy do not appear, confirm that this viral serotype is identical with S1133;
Described virus breeding is seed culture of viruses to be bred go down to posterity on Embryo Gallus domesticus or chick embryo fibroblast;
Described vaccine inactivation is to adopt formalin-inactivated 16 hours, and described formalin concentration is 34%, and addition is 2 ‰ of a deactivation liquor capacity;
Described emulsifying is to add emulsifier tween-80 in aqueous phase liquid, and tween 80 accounts for 1% of water volume, and described aqueous phase liquid is the viral liquid of deactivation, and water and oil phase volume ratio are 3: 5, and wherein oil phase is the emulsifying white oil; Described oil phase is to add aluminium stearate by 2 ‰ in white oil, boils by 5 ‰ adding Si Ben-80 to form; With 12000 rev/mins of emulsifyings 10 minutes, make inactivated vaccine with the mulser mixing material;
Described virus adopted Avianreovirus Avianreovirus, and ARV, strain are the RS13 strain, and preserving number is CGMCC No.1713, was deposited in Chinese microbial preservation administration committee common micro-organisms center on May 16th, 2006;
Described reovirus does not have cyst membrane, is 20 body symmetries, and genome is made of 10 double-stranded RNA segmentations, can tolerate 60 ℃ of 8～10h, and is insensitive to ether, and to the chloroform slight sensitive, to the alkali sensitivity, 3% sodium hydroxide effect 1h can kill virus, no blood clotting characteristic.
2. one kind prepares the method for reovirus inactivated vaccine according to claim 1, it is characterized in that it comprises the steps:
A. the virus of preservation in the claim 1 is bred 35～45 generations of going down to posterity on Embryo Gallus domesticus, results virus detects its virus titer and reaches 10
10.5ELD
50/ 0.2ml uses viral seed as producing;
B. serum detects: with in the S1133 positive serum and after, inoculate in 10 age in days SPF Embryo Gallus domesticus or the chick embryo fibroblast, corresponding Embryo Gallus domesticus body and internal organs pathological changes or corresponding cytopathy do not appear, confirm that this viral serotype is identical with S1133;
C. virus breeding: seed culture of viruses bred on Embryo Gallus domesticus or chick embryo fibroblast go down to posterity, virus titer is detected reach 10
10.5ELD
50/ 0.2ml;
D. vaccine inactivation: formalin-inactivated 16 hours, described formalin concentration is 34%, addition is 2 ‰ of a deactivation liquor capacity;
E. oil phase preparation: in white oil, add aluminium stearate, add Si Ben-80 by 5 ‰ and boil and form by 2 ‰;
F. emulsifying: add emulsifier tween-80, tween 80 accounts for 1% of water volume, and water and oil phase volume ratio are 3: 5, and described water is the viral liquid of deactivation, and oil phase is the emulsifying white oil; With 12000 rev/mins of emulsifyings 10 minutes, make inactivated vaccine with mulser.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610012792XA CN1895667B (en) | 2006-06-06 | 2006-06-06 | Reovirus inactivated vaccine and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610012792XA CN1895667B (en) | 2006-06-06 | 2006-06-06 | Reovirus inactivated vaccine and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1895667A CN1895667A (en) | 2007-01-17 |
| CN1895667B true CN1895667B (en) | 2010-11-03 |
Family
ID=37608410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610012792XA Active CN1895667B (en) | 2006-06-06 | 2006-06-06 | Reovirus inactivated vaccine and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1895667B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526721B (en) * | 2011-11-11 | 2013-09-04 | 中国水产科学研究院长江水产研究所 | Inactivated vaccine for ictalurus punctatus hemorrhage disease, as well as preparation method and application thereof |
| CN103184194B (en) * | 2011-12-29 | 2015-07-15 | 普莱柯生物工程股份有限公司 | Production of avian reovirus and vaccine by using mammalian cell line |
| CN103123351B (en) * | 2012-11-12 | 2015-02-25 | 福州大北农生物技术有限公司 | Method for testing exogenous virus of SPF (specific pathogen free) egg |
| CN103479997B (en) * | 2013-09-23 | 2015-05-20 | 天津瑞普生物技术股份有限公司 | Preparation method for avian reovirus virus water-in-oil-in-water type inactivated vaccines |
| ES2954910T3 (en) * | 2014-10-03 | 2023-11-27 | Intervet Int Bv | Broad-spectrum vaccine against avian reovirus |
| CN106215185A (en) * | 2016-08-31 | 2016-12-14 | 天津瑞普生物技术股份有限公司 | A kind of preparation method of the multi-joint subunit vaccine of Avianreovirus |
| CN106540250A (en) * | 2016-11-30 | 2017-03-29 | 山东农业大学 | The preparation method of goose source reovirus inactivated vaccine |
| CN108659122B (en) * | 2018-05-22 | 2020-04-14 | 山东农业大学 | A kind of egg yolk antibody for preventing and treating new chicken reovirus and preparation method thereof |
| CN108379574B (en) * | 2018-05-22 | 2020-03-31 | 山东农业大学 | A kind of inactivated vaccine for preventing and treating new chicken reovirus and preparation method thereof |
| CN108660117B (en) * | 2018-05-22 | 2020-10-23 | 山东农业大学 | A novel chicken reovirus causing arthritis in broilers and its application |
| CN116042537B (en) * | 2022-10-21 | 2024-09-20 | 乾元浩生物股份有限公司 | Avian reovirus strain QYH2020-QD, virus liquid, preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1616094A (en) * | 2004-09-21 | 2005-05-18 | 中国科学院武汉病毒研究所 | Preparation method of grass carp reovirus antigen subunit vaccine |
| CN1218748C (en) * | 2001-12-19 | 2005-09-14 | 福建省农业科学院畜牧兽医研究所 | Foreign duck liver ichthyophthirius active vaccine and preparation method thereof |
| CN100516206C (en) * | 2006-06-06 | 2009-07-22 | 瑞普（保定）生物药业有限公司 | A kind of reovirus vaccine and its preparation method |
-
2006
- 2006-06-06 CN CN200610012792XA patent/CN1895667B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1218748C (en) * | 2001-12-19 | 2005-09-14 | 福建省农业科学院畜牧兽医研究所 | Foreign duck liver ichthyophthirius active vaccine and preparation method thereof |
| CN1616094A (en) * | 2004-09-21 | 2005-05-18 | 中国科学院武汉病毒研究所 | Preparation method of grass carp reovirus antigen subunit vaccine |
| CN100516206C (en) * | 2006-06-06 | 2009-07-22 | 瑞普（保定）生物药业有限公司 | A kind of reovirus vaccine and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1895667A (en) | 2007-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1895667B (en) | Reovirus inactivated vaccine and its preparation | |
| CN104814985A (en) | Application of seaweed polysaccharides | |
| CN102260649B (en) | Infectious bursal disease virus (IBDV) and method for preparing inactivated vaccines and combined vaccines by breeding IBDV with chick-embryo cell system and bioreactor | |
| CN102258777B (en) | Method for preparing inactivated vaccine and combined vaccine by breeding infectious bursal disease virus (IBDV) by chicken embryo source cell line | |
| CN106119212B (en) | Fowl adenovirus strain, inactivated vaccine and preparation method | |
| CN103059131A (en) | Method for preparing bivalent yolk antibody for preventing and treating duck virus hepatitis I and III | |
| CN104250637B (en) | One plant of bird flu H9N2 subtype virus strain and its application | |
| Guo et al. | Immunoregulatory effects of Taishan Pinus massoniana pollen polysaccharide on chicks co-infected with avian leukosis virus and Bordetella avium early in ovo | |
| CN102816740B (en) | Avian influenza virus, inactivated vaccine and method for preparing same | |
| CN102304494B (en) | Duck hemorrhagic ovaritis virus strain, inactivated vaccine and preparation method thereof | |
| CN109207436B (en) | Group I type 4 avian adenovirus strain and application thereof | |
| CN104258389B (en) | A kind of vaccine combination and its preparation method and application | |
| CN103495167B (en) | A kind of preparation method of chicken infection bursal disease composite live vaccine | |
| CN103937753B (en) | H9N2 subtype avian influenza virus strain and inactivated vaccine thereof and application | |
| CN114395536B (en) | Avian adenovirus type 4, 8 and 11 trivalent vaccine and preparation method and application thereof | |
| CN108465107B (en) | Duck type 2 adenovirus and Muscovy duck parvovirus disease combined inactivated vaccine | |
| CN100516206C (en) | A kind of reovirus vaccine and its preparation method | |
| CN111778217B (en) | I-group 4 type avian adenovirus SD-F strain, inactivated vaccine and preparation method | |
| CN105770892A (en) | Preparation method of biological veterinary drug for preventing and treating hydropericardium hepatitis syndrome in chickens | |
| CN101480492B (en) | Combined inactivated vaccine for against infectious brunchitis and newcastle disease and preparation method thereof | |
| CN101638661A (en) | Construction of recombinant lactic acid bacteria with HN gene and F gene of Newcastle disease virus | |
| CN108969760B (en) | A kind of method and vaccine with LMH cell line production 4 type vaccine of aviadenovirus | |
| CN102558347A (en) | Yolk antibody for treating bird flu and infectious bronchitis and preparation method thereof | |
| CN102533673B (en) | Chicken infectious bursal disease very virulent cell adapted strain and application thereof | |
| CN109207437A (en) | One plant of 8 type aviadenovirus strain of I group and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200323 Address after: 300000 No.1, Dongjiu Road, Tianjin pilot free trade zone (Airport Economic Zone) Patentee after: TIANJIN RINGPU BIO-TECHNOLOGY Co.,Ltd. Address before: 071000 No. 793 Tengfei Road, private science and Technology Park, Hebei, Baoding Patentee before: RINGPU (BAODING) BIOLOGICAL PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231204 Address after: 511300 High tech Industrial Base in Zengjiang Street East District, Zengcheng, Guangzhou, Guangdong Province Patentee after: GUANGZHOU SOUTH CHINA BIOLOGICAL MEDICINE Co.,Ltd. Address before: No. 1 East Jiudao, Tianjin Pilot Free Trade Zone (Airport Economic Zone), 300000 Patentee before: TIANJIN RINGPU BIO-TECHNOLOGY Co.,Ltd. |